Part ofFDA →

FEDERALhearing transcript

High Impact

Congressional Hearing: FDA Oversight of the Infant Formula Shortage

Original title: FDA OVERSIGHT PART I: THE INFANT FORMULA SHORTAGE

January 1, 2023

FDA infant formula food safety government oversight supply chain

Track this bill to get notified when it advances a stage. One tap to stop, anytime.

The Frame

What this does

The hearing examines the federal government's role in managing food safety and supply chain stability, which directly impacts the availability and safety of infant formula for families nationwide.

Who is mentioned in the record

Potentially affected actors named in the source documents. Mention is not a position.

Parents and caregivers

The availability and safety of infant formula directly impacts their ability to feed infants.

FDA

The agency is subject to congressional oversight regarding its inspection protocols and food safety management.

What changed

Last recorded activity January 1, 2023.

What's next

Next step not available in the current record.

Summary

This hearing transcript documents a March 2023 Congressional oversight meeting regarding the FDA's response to the national infant formula shortage. Lawmakers and experts discussed the causes of the crisis, the agency's inspection processes, and strategies to prevent future supply disruptions.

Key Facts

The hearing took place on March 28, 2023, in the Rayburn House Office Building.
The FDA is responsible for overseeing 78 percent of the U.S. food supply.
The hearing focused on identifying failures in the FDA's response to the infant formula shortage.
Witnesses included Frank Yiannas (former FDA Deputy Commissioner) and Dr. Peter Lurie (Center for Science in the Public Interest).
The committee reviewed written statements from the Consumer Brands Association, Consumer Reports, and the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition.
Questions for the record were submitted to witnesses by Rep. McClain and Rep. Porter.

Frequently Asked Questions

What was the purpose of this hearing?

To investigate how the infant formula shortage occurred, evaluate the FDA's response, and determine if the agency is prepared to prevent future crises.

Who testified at the hearing?

Frank Yiannas, former Deputy Commissioner of the FDA's Office of Food Policy & Response, and Dr. Peter Lurie, President of the Center for Science in the Public Interest.

Why It Matters

The hearing examines the federal government's role in managing food safety and supply chain stability, which directly impacts the availability and safety of infant formula for families nationwide.

News Coverage

No news coverage found yet. Articles are indexed twice daily.

Discoveries

Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.

policy shift90% confidence

FDA Inspection Criticism

The hearing highlights a shift toward increased legislative scrutiny of the FDA's inspection frequency and its justification of performance delays during the pandemic.

Food and Drug Administration

Connected Entities

personLisa McClain“Chairwoman of the Subcommittee on Health Care and Financial Services”Map →

personPeter Lurie“President & Executive Director, Center for Science in the Public Interest”Map →

personFrank Yiannas“Former Deputy Commissioner, Office of Food Policy & Response, FDA”Map →

organizationFood and Drug Administration“The federal agency under oversight regarding food safety and inspections”Map →

organizationSubcommittee on Health Care and Financial Services“The congressional body conducting the hearing”Map →

Sources

Open source document

www.govinfo.gov

Analysis Score

0–100

Significance75
How much this matters to a regular citizen
Controversy60
Intensity of disagreement among stakeholders
Entertainment20
Compellingness for a non-policy-wonk reader
Buzz30
Current news / social attention level

Publisher tools